Zanganeh Mahkam 4
4 · Summit Therapeutics Inc. · Filed Jun 12, 2026
Research Summary
AI-generated summary of this filing
Summit Therapeutics (SMMT) CEO Mahkam Buys 3.81M Shares
What Happened
Zanganeh Mahkam, CEO of Summit Therapeutics, reported an open-market purchase of 3,810,000 shares at $13.12 per share on 2026-06-12, for a total transaction value of $49,987,200. This was a direct purchase (transaction code P) rather than a sale or option exercise.
Key Details
- Transaction date: 2026-06-12; Price: $13.12 per share; Shares acquired: 3,810,000; Total value: $49,987,200.
- Transaction type/code: P (purchase) — open market or private purchase.
- Shares owned after transaction: Not specified in the Form 4 filing.
- Footnote: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest (per footnote F1).
- Filing timeliness: Form 4 was filed covering the transaction dated 2026-06-12 (no late filing indicated).
Context
This report documents a sizable insider purchase, which investors often view as a notable insider buy, but the filing does not state motive. The filing is a straight equity purchase (not an option exercise, gift, or tax-related withholding).
Insider Transaction Report
Form 4
Zanganeh Mahkam
DirectorCo-Chief Executive Officer10% Owner
Transactions
- Purchase
Common Stock
[F1]2026-06-12$13.12/sh+3,810,000$49,987,200→ 573,883,879 total(indirect: By Spouse)
Holdings
- 25,824,474(indirect: By Trust)
Common Stock
[F1] - 76,680(indirect: Immediate family member)
Common Stock
[F1] - 10,199,776(indirect: By Trust)
Common Stock
[F1] - 31,000
Common Stock
Footnotes (1)
- [F1]The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Signature
/s/ Mahkam Zanganeh|2026-06-12